Evidence map›Paper›PMID 36120311›Full record

ArticleFrontiers in pharmacology2022

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects.

James Brown, Zhe Li, Xi Wang, Yu Jeong Kim, Yu-Chen Wang, Yanning Zuo, Weizhe Hong, Pin Wang, Bo Li, Lili Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

James BrownDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
Zhe LiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
Xi WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
Yu Jeong KimDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
Yu-Chen WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
Yanning ZuoDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Weizhe HongDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Pin WangDepartment of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, United States.
Bo LiDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
Lili YangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, United States.
University of California, Los Angeles · USBroad Center · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MAOIs, a well-established class of antidepressant that operate through the inhibition of monoamine oxidase to increase available serotonin, have recently been identified as a surprisingly effective candidate for the circumvention of tumor-induced immune suppression due to their abilities to enhance antitumor T cell activity through autocrine serotonin signaling and depolarize alternatively activated tumor-associated macrophages through a reduction in reactive oxygen species production. However, this impressive class of antidepressants-turned-cancer-drugs can induce aggressive behavioral side effects when administered in immunotherapeutic doses. In this study, we investigated the possibility of avoiding these neurological side effects while simultaneously improving antitumor activity by establishing crosslinked multilamellar liposomal vesicles (cMLVs) containing the MAOI phenelzine (PLZ). Our results showed that cMLV-PLZ treatment increases antitumor efficacy in a B16-OVA mouse melanoma model compared to treatment with free phenelzine. We also found that nanoformulation resulted in the complete elimination of MAOI-related aggression. These findings suggest a promising direction for the future of MAOIs repurposed for cancer immunotherapies.

Indexed as

cancer immunotherapycrosslinked multilamellar liposomal vesiclesimmune checkpoint blockademonoamine oxidase inhibitorsnanoformulationneurological side effectsphenelzineserotonin

Identifiers

PMID36120311
PMCPMC9475110
OpenAlexW4294324933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.